NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-172-2017-1-FR-01 METHOD FOR DETERMINING LYMPHOMA TYPE FR EP 18733500.5 Issued
NCI E-172-2017-1-DE-01 METHOD FOR DETERMINING LYMPHOMA TYPE DE EP 18733500.5 Issued
NCI E-172-2017-1-EP-02 METHOD FOR DETERMINING LYMPHOMA TYPE EP National Stage 18733500.5 Issued
NCI E-172-2017-1-GB-01 METHOD FOR DETERMINING LYMPHOMA TYPE GB EP 18733500.5 Issued
NIDA E-109-2019-0-US-01 THE DESIGN AND SYNTHESIS OF FENTANYL HAPTENS FOR A BIFUNCTIONAL HEROIN-FENTANYL VACCINE US 62/960,187 Abandoned
NCI E-265-2015-0-US-16 T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS US CON 16/739,310 11667692 Issued PDF
NCI E-050-2014-0-JP-17 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon JP DIV 2020-001954 Abandoned
NCI E-091-2019-0-US-01 METHODS OF PRODUCING T CELL POPULATIONS USING INDUCED PLURIPOTENT STEM CELLS US 62/957,939 Abandoned
NCI E-140-2017-0-JP-06 COMPOUNDS FOR TREATING CANCER JP National Stage 2020-500657 Issued
NCI E-140-2017-0-US-07 ENGLERIN DERIVATIVES FOR TREATMENT OF CANCER US National Stage 16/628,768 11098054 Issued PDF
NCI E-028-2015-1-EP-15 Anti-Mutated Kras T Cell Receptors EP DIV 20150279.6 Issued
NCI E-028-2015-1-GB-01 Anti-Mutated Kras T Cell Receptors GB EP 20150279.6 Issued
NCI E-028-2015-1-IT-01 Anti-Mutated Kras T Cell Receptors IT EP 20150279.6 Issued
NCI E-028-2015-1-IE-01 Anti-Mutated Kras T Cell Receptors IE EP 20150279.6 Issued
NCI E-028-2015-1-DE-01 Anti-Mutated Kras T Cell Receptors DE EP 20150279.6 Issued
NCI E-028-2015-1-HU-01 Anti-Mutated Kras T Cell Receptors HU EP 20150279.6 Issued
NCI E-028-2015-1-NL-01 Anti-Mutated Kras T Cell Receptors NL EP 20150279.6 Issued
NCI E-028-2015-1-FR-01 Anti-Mutated Kras T Cell Receptors FR EP 20150279.6 Issued
NCI E-028-2015-1-ES-01 Anti-Mutated Kras T Cell Receptors ES EP 20150279.6 Issued
NCI E-028-2015-1-SE-01 Anti-Mutated Kras T Cell Receptors SE EP 20150279.6 Issued
NCI E-028-2015-1-CH-01 Anti-Mutated Kras T Cell Receptors CH EP 20150279.6 Issued
NCI E-028-2015-1-TR-01 Anti-Mutated Kras T Cell Receptors TR EP 20150279.6 Issued
NCI E-028-2015-1-AT-01 Anti-Mutated Kras T Cell Receptors AT EP 20150279.6 Issued
NCI E-028-2015-1-BE-01 Anti-Mutated Kras T Cell Receptors BE EP 20150279.6 Issued
NCI E-140-2017-0-DE-08 COMPOUNDS FOR TREATING CANCER DE EP 18745789.0 Issued
NCI E-140-2017-0-ES-09 COMPOUNDS FOR TREATING CANCER ES EP 18745789.0 Issued
NCI E-140-2017-0-FR-10 COMPOUNDS FOR TREATING CANCER FR EP 18745789.0 Issued
NCI E-140-2017-0-GB-11 COMPOUNDS FOR TREATING CANCER GB EP 18745789.0 Issued
NCI E-140-2017-0-EP-05 COMPOUNDS FOR TREATING CANCER EP National Stage 18745789.0 Issued
NIDCR E-186-2019-0-US-01 NEW COMPOSITIONS AND METHODS FOR PROMOTING PERIODONTAL HEALTH US 62/957,051 Abandoned
NCI E-046-2020-0-US-01 INHIBITION OF ACTIVE TUMOR DEFENSE TO IMPROVE IMMUNOTHERAPY EFFICACY AND USES THEREOF US 62/956,955 Abandoned
NCI E-140-2017-0-CA-04 COMPOUNDS FOR TREATING CANCER CA National Stage 3068980 Pending
NCI E-040-2019-0-CN-05 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors CN National Stage 202080008456.6 Issued
NCI E-050-2014-0-EP-16 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON EP DIV 20150087.3 Issued
NCI E-040-2019-0-PCT-02 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors PCT PCT PCT/US2020/012021 Expired
NCI E-040-2019-0-EP-06 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors EP National Stage 20703568.4 Pending
NCI E-040-2019-0-CA-04 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors CA National Stage 3125484 Pending
NCI E-040-2019-0-AU-03 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors AU National Stage 2020206308 Pending
NCI E-140-2017-0-AU-03 COMPOUNDS FOR TREATING CANCER AU National Stage 2018297271 Issued
NCI E-175-2016-0-SG-14 ANTI-KRAS-G12D T CELL RECEPTORS SG DIV 10201913959W Pending
NCI E-028-2015-1-SG-16 Anti-Mutated Kras T Cell Receptors SG DIV 10201913978R Pending
NCI E-183-2017-0-CN-06 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains CN National Stage 201880044208.X Issued
NIA E-151-2017-0-US-10 FATTY ACID DERIVATIVES AND THEIR USE US National Stage 16/622,697 11555021 Issued PDF
NIAID E-158-2021-0-US-01 Compositions And Methods For Treating Bacterial Infections US 62/954,998 Abandoned
NCI E-265-2015-0-SG-17 T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS` SG DIV 10201913868X Pending
NCI E-282-2016-2-SG-01 Methods For Pre-conditioning Patients For Cell Therapy SG DIV 10201913613S Abandoned
NCI E-282-2016-2-SG-02 Methods For Pre-conditioning Patients For Cell Therapy SG DIV 10201913604T Abandoned
NCI E-183-2017-0-US-13 ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS US National Stage 16/626,991 Abandoned
NEI E-162-2016-0-JP-09 GENE THERAPY FOR RETINITIS PIGMENTOSA JP DIV 2019-235539 Issued
NCI E-085-2013-0-AU-14 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood AU DIV 2019284080 Issued